By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – www.careers.regeneron


Key Statistics


Email:
Ownership: Public

Web Site: Regeneron Pharmaceuticals, Inc.
Employees: 2300+
Symbol: REGN
 



Industry
Biotechnology


Collaborations

Sanofi US 

Bayer Corporation 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotechnologies 





Company News
Regeneron Pharmaceuticals, Inc. (REGN) To Ring The NASDAQ Stock Market Opening Bell 8/20/2014 7:32:11 AM
Regeneron Pharmaceuticals, Inc. (REGN) To Ring The NASDAQ Stock Market Opening Bell 8/19/2014 10:34:59 AM
Regeneron Pharmaceuticals, Inc. (REGN) Announces Upcoming 2014 Investor Conference Presentations 8/19/2014 8:23:10 AM
Booming Regeneron Pharmaceuticals, Inc. (REGN) On Track With Plan To Nearly Double Employee Count By 2019, Talks Strategies For Making Money 8/6/2014 6:10:07 AM
Regeneron Pharmaceuticals, Inc. (REGN) Reports Second Quarter 2014 Financial and Operating Results 8/5/2014 7:39:51 AM
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Bag BioMarin Pharmaceutical Inc. (BMRN)'s Special FDA Priority Review Voucher For $67.5 Million 7/30/2014 3:51:46 PM
Regeneron Pharmaceuticals, Inc. (REGN) Release: EYLEA® (aflibercept) Injection Receives FDA Approval For The Treatment Of Diabetic Macular Edema (DME) 7/30/2014 7:57:29 AM
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Alirocumab Cuts Cholesterol In Nine Late-Stage Trials 7/30/2014 6:20:57 AM
Regeneron Pharmaceuticals, Inc. (REGN) To Report Second Quarter 2014 Financial And Operating Results And Host Conference Call And Webcast On August 5, 2014 7/21/2014 12:54:44 PM
Regeneron Pharmaceuticals, Inc. (REGN) Release: Two-Year Results From Phase 3 VIVID-DME Trial Of EYLEA® (aflibercept) Injection For The Treatment Of Diabetic Macular Edema Show Sustained Improvement In Vision 7/18/2014 9:20:28 AM
12345678910...
//-->